Abstracts tagged "Morphea"

Abstract Number: 030 • 2023 Pediatric Rheumatology Symposium
International Validation of the Total Morbidity Score for Juvenile Localized Scleroderma: 2023 Update
Christina ZIgler¹, Debra Henke², Clare Pain³, Hanna Lythgoe³, Kaveh Ardalan², Kathryn Torok⁴ and Suzanne Li⁵, ¹Duke, Durham, NC, ²Duke University School of Medicine, Durham, NC, ³Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, Hackensack, NJ
Background/Purpose: Juvenile localized scleroderma (jLS) is a rare condition causing inflammation and fibrosis that may impair health-related quality of life (HRQoL). Recent studies demonstrate extracutaneous…
Abstract Number: 117 • 2020 Pediatric Rheumatology Symposium
Family Impact of Juvenile Localized Scleroderma
Katia Milovanova¹, Vimal Prajapati ², Merna Adly ², Rebeka Stevenson ³, Brendan Lethebe ² and Nadia Luca ², ¹University of Alberta, Edmonton, Alberta, Canada, ²University of Calgary, Calgary, Alberta, Canada, ³Cochrane, Alberta, Canada
Background/Purpose: Juvenile localized scleroderma (jLS) is a rare autoimmune disease that can lead to significant morbidity. Previous studies have focused on predictors of patient health-related…
Abstract Number: 794 • 2019 ACR/ARP Annual Meeting
Mycophenolate Mofetil for the Treatment of Severe or Methotrexate-refractory Juvenile Localized Scleroderma
Laura Saggioro ¹, Giorgia Martini ¹, Roberta Culpo ¹, Alessandra Meneghel ¹ and Francesco Zulian², ¹Dept. of Woman's and Child's Health, University of Padua, Italy, Padua, Italy, ²Department of Woman and Child Health, University of Padua, Italy, Padova, Italy
Background/Purpose: Juvenile Localized Scleroderma (JLS), includes a number of conditions characterized by skin thickening with varying degree of severity. Many patients, particularly those with the…
Abstract Number: 1053 • 2019 ACR/ARP Annual Meeting
Parallel Analysis of Systemic Sclerosis and Keloidal Morphea Skin Biopsies Delineates the Hallmark Profibrotic Gene Expression Profile for Scleroderma in Vivo
Kristina Clark¹, Corrado Campochiaro ¹, Nataliya Gak ¹, Emma Derrett-Smith ¹ and Christopher Denton ², ¹University College London, London, United Kingdom, ²University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom
Background/Purpose: We have examined whole skin biopsy gene expression by RNAseq in a rare subgroup of scleroderma with both systemic sclerosis (SSc) and concurrent keloidal…
Abstract Number: 1241 • 2019 ACR/ARP Annual Meeting
Further Characterizing Morphea Subsets Using a Multi-center, Prospective, Cross-sectional Analysis of Morphea in Adults and Children
Smriti Prasad¹, Kaila L. Schollaert ², Robert Haley ¹, Kathryn Torok ³ and Heidi Jacobe ¹, ¹University of Texas Southwestern Medical Center, Dallas, ²University of Pittsburgh, Pittsburgh, ³UPMC Children's Hospital of Pittsburgh, Pittsburgh
Background/Purpose: There have been few large, prospective cohort studies performed on morphea, or localized scleroderma. Most that exist focus exclusively on either pediatric or adult…
Abstract Number: 1420 • 2018 ACR/ARHP Annual Meeting
Prospective Validation of Cone Beam Computed Tomography for the Assessment of Disease Progression in Linear Scleroderma of the Face
Alessandra Meneghel¹, Stefano Puggina², Eleni Kamburi³, Giorgia Martini³, Fabio Vittadello³ and Francesco Zulian¹, ¹University of Padua, Department of Woman and Child Health, Padua, Italy, ²Unix Radiology Service, Affidea Group, Piove di Sacco, Italy, ³Department of Woman and Child Health, University of Padua, Padua, Italy
Background/Purpose: Currently, the techniques used for the monitoring of Localized Scleroderma of the face (LSF) have significant limitations. We prospectively evaluated the reliability of the…
Abstract Number: 1419 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcome of 50 Patients with Linear Scleroderma Treated with Methotrexate
Giorgia Martini¹, Gloria Fadanelli¹, Anna Agazzi¹, Fabio Vittadello¹, Alessandra Meneghel² and Francesco Zulian², ¹Department of Woman and Child Health, University of Padua, Padua, Italy, ²University of Padua, Department of Woman and Child Health, Padua, Italy
Background/Purpose: Linear Scleroderma (LS) is the most common subtype of localized Scleroderma in children and the one most frequently associated with tissue damage and functional…
Abstract Number: 1284 • 2017 ACR/ARHP Annual Meeting
The Localized Scleroderma Quality of Life Instrument (LoSQI): Initial Validation in Pediatric Localized Scleroderma
Christina K. Zigler¹, Kaveh Ardalan², Kaila Schollaert-Fitch³, Heidi Jacobe⁴ and Kathryn S. Torok³, ¹Physical Medicine & Rehabilitation, University of Pittsburgh, Pittsburgh, PA, ²Division of Rheumatology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ³Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ⁴Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: There is a current need to integrate health related quality of life (HRQoL) into outcomes for clinical trials (Chang & Reeve, 2005). For pediatric…
Abstract Number: 1287 • 2017 ACR/ARHP Annual Meeting
Cone Beam Computed Tomography for the Assessment of Linear Scleroderma of the Face
Francesco Zulian¹, Chiara Di Giovanni², Stafano Puggina³, Alessandra Meneghel¹, Sabina Trainito⁴ and Giorgia Martini², ¹University of Padua, Department of Woman and Child Health, Padua, Italy, ²Department of Woman and Child Health, University of Padua, Padua, Italy, ³Unix Radiology Service, Affidea Group inc., Piove di Sacco, Italy, ⁴Division of Physical Medicine and Rehabilitation, University of Padua, Padua, Italy
Background/Purpose: Linear scleroderma of the face (LSF) is a very disabling condition and, to date, standardized and validated methods for assessing and monitoring the disease…
Abstract Number: 2346 • 2017 ACR/ARHP Annual Meeting
Chemokine Ligand 9 (CXCL9) [Monokine Induced By Gamma Interferon (MIG)] As a Predictor of Active Disease Status in Localized Scleroderma
Kathryn S. Torok¹, Qi Mi², Emily Mirizio³, Kaila Schollaert-Fitch¹, Mark Fritzler⁴ and Marvin J. Fritzler⁵, ¹Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ²Department of Sports Medicine and Nutrition, University of Pittsburgh, Pittsburgh, PA, ³Pediatric Rhuematology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ⁴Eve Technologies, Calgary, AB, Canada, ⁵Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Localized scleroderma (LS) is a fibrotic autoimmune disease of the skin and underlying tissues which can lead to disfiguring sequlea, especially in childhood-onset. Untreated…
Abstract Number: 1026 • 2016 ACR/ARHP Annual Meeting
Morphea-like Skin Lesions Reported in the Phase 3 Long-Term Odanacatib Fracture Trial and Extension in Postmenopausal Women with Osteoporosis
Kenneth G. Saag¹, Tobie de Villiers², Peter Alexandersen³, Heidi Jacobe⁴, Carrie Kovarik⁵, Victoria P. Werth⁶, Albert Leung⁷, Avani Desai-Merchant⁸, Julie Mattaliano⁸ and Deborah Gurner⁸, ¹Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA, Birmingham, AL, ²Mediclinic Panorama and Department of Obstetrics & Gynecology, University of Stellenbosch, Cape Town, South Africa, Cape Town, South Africa, ³Center for Clinical and Basic Research, Vejle, Denmark, Ballerup, Denmark, ⁴Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ⁶Philadelphia VAMC, Philadelphia, PA, USA, Philadelphia, PA, ⁷Formerly Merck & Co., Inc., Kenilworth, NJ, USA, Kenilworth, NJ, ⁸Merck & Co., Inc., Kenilworth, NJ, USA, Kenilworth, NJ
Background/Purpose: LOFT was a double-blind, placebo-controlled trial. Women ≥65 years with total hip (TH) or femoral neck (FN) bone mineral density (BMD) T-score ≤-2.5, or…
Abstract Number: 2392 • 2016 ACR/ARHP Annual Meeting
Establishing Quality of Life Content Domains in Pediatric Localized Scleroderma
Christina K. Zigler¹, Kaveh Ardalan² and Kathryn S. Torok³, ¹University of Pittsburgh, Pittsburgh, PA, ²Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ³Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA
Background/Purpose: Localized scleroderma (LS) can affect patients' physical function and psychosocial well-being, but, published studies of the impact of pediatric LS on health-related quality of…
Abstract Number: 2394 • 2016 ACR/ARHP Annual Meeting
Patient and Parent Global Assessments of Disease Impact in Pediatric Localized Scleroderma: Correlates of Patient Reported Health-Related Quality of Life and Parent Reported Family Impact Domains
Kaveh Ardalan¹, Kaila Schollaert-Fitch², Christina K. Zigler³, Makenzie A. Zidek⁴ and Kathryn S. Torok⁵, ¹Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ²Division of Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ⁵Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA
Background/Purpose: Pediatric localized sclerodermaÕs (LS) effects on patient/family well-being are underexplored. Contributions of HRQoL domains and family dynamics to LSÕs impact on patients has not…
Abstract Number: 417 • 2015 ACR/ARHP Annual Meeting
Gender Differences in Pediatric Localized Scleroderma: Clinical and Patient-Reported Outcomes
Kaveh Ardalan¹, Nicole Hershey¹, Jonathan Yabes², Eveline Wu³, Suzanne C. Li⁴, Robert C. Fuhlbrigge⁵, C. Egla Rabinovich⁶, Kathryn S. Torok¹ and The CARRA Registry Investigators, ¹Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ³Pediatrics, University of North Carolina - Chapel Hill, Chapel Hill, NC, ⁴Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ⁵Program in Rheumatology, Division of Immunology, Boston Children’s Hospital, Boston, MA, ⁶Pediatric Rheumatology, Duke University Medical Center, Durham, NC
Background/Purpose: Localized scleroderma (LS) is an autoimmune disease of the skin and underlying tissue that leads to progressive fibrosis and disability in growing children. Pediatric…
Abstract Number: 418 • 2015 ACR/ARHP Annual Meeting
Relationship of Race, Ethnicity, and Outcomes in Pediatric Localized Scleroderma: Possible Differences in Disease Activity
Kaveh Ardalan¹, Nicole Hershey¹, Jonathan Yabes², Kathryn S. Torok¹ and The CARRA Registry Investigators, ¹Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Pediatric localized scleroderma (LS) is an autoimmune skin and soft tissue disease that causes morbidity via progressive skin fibrosis and extracutaneous manifestations (ECMs), such…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].